Expanded exclusion lists also could impact pharmacies, patients. Read More »

Cigna Corp. may receive additional price discounts from pharmaceutical companies should new cholesterol medications prove less effective than expected — a move marks a crucial step in a broader initiative to link the cost of medications to their efficacy. Read More »

Alex Brill, CEO of Washington, D.C.-based economic policy consulting firm Matrix Global Advisors, recently published a strategic proposal suggesting how payors can support biosimilar utilization. Read More »

With superbugs posing a significant health risk to the elderly, an expert from the Centers for Disease Control and Prevention (CDC) recently spoke with American Pharmacy about the agency's recommendations for the nation's nursing homes and hospitals to stop the spread of antibiotic-resistant organisms. Read More »

Jonathan Small, C.P.A. and president of Oklahoma Council of Public Affairs (OCPA), recently wrote a “Free Market Friday” op-ed for The Journal Record to promote freedom in the delivery and payment of health care, showing how Oklahoma is better off not accepting funds to support the Affordable Care Act (ACA). Read More »

With health care spending on an upward trajectory, Alex Brill, CEO of economic policy consulting firm Matrix Global Advisors, thinks that value within the sector also must increase. Read More »

Zurampic has been approved by the FDA for treatment of hyperuricemia associated with gout. Read More »

Oklahoma consumers enrolled in health plans with insurance deductibles that are yet to be reached and those who are uninsured may bear the high costs of rising drug prices, thanks to a proposed piece of legislation that would give pharmacies permission to disregard negotiated discounts with insurers and transfer the price hikes on to consumers. Read More »

AMCP recognizes Prime pharmacists with Fellow and New Practitioner awards. Read More »

Citizens Against Government Waste continues to oppose state or federal legislation that would enact an “Any Willing Provider” provision to Medicare Part D. Read More »

Various states have enacted or are considering legislation limiting the circumstances under which maximum allowable cost programs (MACs) may be used, a decision that one expert says could result in increased pharmaceutical spending that in turn increases the cost of pharmaceutical coverage. Read More »